A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

NCT03428100 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

463

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Baricitinib
DRUG: Placebo
DRUG: Topical corticosteroid

Sponsor

Eli Lilly and Company

Collaborators

[object Object]